Please login to the form below

Not currently logged in
Email:
Password:

government

This page shows the latest government news and features for those working in and with pharma, biotech and healthcare.

UK government updates the Model Clinical Trials Agreement

UK government updates the Model Clinical Trials Agreement

UK government updates the Model Clinical Trials Agreement. New regulation aims to speed-up R&D. ... Ricky Verrall, head of chief scientist office of the Scottish government, said: “Delivering a single UK agreement streamlines the research environment

Latest news

  • GSK’s R&D head Vallance departs, possibly for government role GSK’s R&D head Vallance departs, possibly for government role

    GSK’ s R&D head Vallance departs, possibly for government role. An independent panel of scientists proposed the UK role to Vallance, according to the FT. ... GlaxoSmithKline’s head of R&D Patrick Vallance could be en route to a UK government position

  • UK signals desire for close post-Brexit relationship with EU UK signals desire for close post-Brexit relationship with EU

    The UK government appears to be ready to take a more pragmatic stance on its post-Brexit approach to medicines regulation. ... ABPI chief executive Mike Thompson said: "This letter is a welcome recognition that the future of medicines regulation is a key

  • UK pharma calls on next government to be more ambitious UK pharma calls on next government to be more ambitious

    UK pharma calls on next government to be more ambitious. ABPI wants medicines access to reach levels of other developed nations. ... The current government led by Theresa May outlined its industrial strategy in January, plans to handed a key role to the

  • Life sciences to play key role in UK’s post-Brexit strategy Life sciences to play key role in UK’s post-Brexit strategy

    May said the model will see the government “ not just stepping back but stepping up to a new, active role”, offering a range of support for tackling industry-specific issues, with “ ... Responding to the proposals, the UK's pharma trade body the

  • May says UK's science base is a May says UK's science base is a "negotiating priority" for Brexit

    The EU response has been guarded, with principle negotiator Donald Tusk saying that at last there was a "more realistic" announcement on Brexit from the UK government, although politicians across the ... Here, I believe the process of, and industry

More from news
Approximately 24 fully matching, plus 1,042 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    Lord Jim O’Neill’s Report on AMR two years ago, supported by the UK Government and the Wellcome Trust, was an important catalyst for action. ... Alongside this, there have been equally important initiatives by the World Health Organization (WHO), the

  • Brexit Means Brexit Brexit Means Brexit

    With the Mansion House speech advocating ‘frictionless’borders and integrated supply chains, the consensus across government and industry is reassuring. ... Paul McGrade agrees: “Pharma should continue to emphasise its constructive solution to both

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    That is why we have submitted a bold new proposal to Government to provide timely access for all eligible patients to our current and future portfolio of cystic fibrosis medicines.

  • The Patient Safety Challenge The Patient Safety Challenge

    We also interviewed key individuals working at government level in the Ministry of Public Health as well as lead educators of doctors and pharmacists at Qatar University.

  • Is trust in healthcare improving? Is trust in healthcare improving?

    major institutions studied - business, government, NGOs and the media. ... This distrust also translates into healthcare policy, with roughly the same proportion agreeing that the government needs to do more to regulate the pharmaceutical industry.

More from intelligence
Approximately 4 fully matching, plus 211 partially matching documents found.

Latest appointments

  • Rubica appoints former GSK executive communications and engagement lead Rubica appoints former GSK executive communications and engagement lead

    Prior to her new role, Gosling spent just under five years at pharma giant GlaxoSmithKline ( GSK) in a range of business leadership roles across communications, employee engagement, multichannel marketing, government affairs

  • Acumen appoints new strategy director Acumen appoints new strategy director

    Bols has also worked in the areas of market access, government affairs, public affairs, health policy and corporate communications to name a few and he has also advised companies engaging with

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... Prior to his time with Pfizer, Maine was

  • IFPMA names new communications director IFPMA names new communications director

    and to enable government to meet ambitious goals such as universal health coverage, global health security and continued innovation in areas of high unmet health needs such as antimicrobial resistance.

  • Ian Weatherhead joins Ipsen Ian Weatherhead joins Ipsen

    He brings 20 years of corporate communications experience within the life sciences sector, most recently at Teva UK/Ireland where he led its corporate communications and government affairs team.

More from appointments
Approximately 2 fully matching, plus 91 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 118 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics